YY-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the FDA, in combination with granulocyte-macrophage Colony-Stimulating factor for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. Co.'s product candidate, 131I-omburtamab, is in development for pediatric central nervous system/leptomeningeal metastases from neuroblastoma - a rare and life-threatening pediatric cancer We show 24 historical shares outstanding datapoints in our YMAB shares outstanding history coverage, used to compute YMAB market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing YMAB market cap history over the course of time is important for investors
interested in comparing YMAB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of YMAB versus a peer is one thing; comparing
YMAB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like YMAB can fluctuate over the course of history.
With this page we aim to empower investors researching YMAB by allowing them to research the YMAB market cap history. |
Free YMAB Email Alerts:
Video: The Importance of Market Cap
